Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.

Dormoi J, Briolant S, Desgrouas C, Pradines B.

Malar J. 2013 Apr 15;12:127. doi: 10.1186/1475-2875-12-127.

2.

Efficacy of proveblue (methylene blue) in an experimental cerebral malaria murine model.

Dormoi J, Briolant S, Desgrouas C, Pradines B.

Antimicrob Agents Chemother. 2013 Jul;57(7):3412-4. doi: 10.1128/AAC.02381-12.

3.

Dose responses of proveblue methylene blue in an experimental murine cerebral malaria model.

Dormoi J, Pradines B.

Antimicrob Agents Chemother. 2013 Aug;57(8):4080-1. doi: 10.1128/AAC.00634-13. No abstract available.

4.

Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.

Dormoi J, Briolant S, Pascual A, Desgrouas C, Travaillé C, Pradines B.

Malar J. 2013 Aug 30;12:302. doi: 10.1186/1475-2875-12-302.

5.

Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Wilson NO, Solomon W, Anderson L, Patrickson J, Pitts S, Bond V, Liu M, Stiles JK.

PLoS One. 2013 Apr 5;8(4):e60898. doi: 10.1371/journal.pone.0060898.

6.

Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, Baret E, Amalvict R, Soulard R, Rogier C, Pradines B.

Malar J. 2012 Jan 10;11:13. doi: 10.1186/1475-2875-11-13.

7.

Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria.

Guo J, Guiguemde AW, Bentura-Marciano A, Clark J, Haynes RK, Chan WC, Wong HN, Hunt NH, Guy RK, Golenser J.

Antimicrob Agents Chemother. 2012 Jan;56(1):163-73. doi: 10.1128/AAC.05006-11.

8.

Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B.

Malar J. 2010 May 25;9:139. doi: 10.1186/1475-2875-9-139.

9.

Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin.

Dormoi J, Pascual A, Briolant S, Amalvict R, Charras S, Baret E, Huyghues des Etages E, Feraud M, Pradines B.

Antimicrob Agents Chemother. 2012 Jun;56(6):3467-9. doi: 10.1128/AAC.06073-11. No abstract available.

10.

Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice.

Recuenco FC, Takano R, Chiba S, Sugi T, Takemae H, Murakoshi F, Ishiwa A, Inomata A, Horimoto T, Kobayashi Y, Horiuchi N, Kato K.

Malar J. 2014 Dec 11;13:487. doi: 10.1186/1475-2875-13-487.

11.

The novel ETA receptor antagonist HJP-272 prevents cerebral microvascular hemorrhage in cerebral malaria and synergistically improves survival in combination with an artemisinin derivative.

Dai M, Freeman B, Bruno FP, Shikani HJ, Tanowitz HB, Weiss LM, Reznik SE, Stephani RA, Desruisseaux MS.

Life Sci. 2012 Oct 15;91(13-14):687-92. doi: 10.1016/j.lfs.2012.07.006.

12.

Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria.

Kobbe R, Schreiber N, May J, Jacobs T.

Antimicrob Agents Chemother. 2008 Apr;52(4):1583-4. doi: 10.1128/AAC.01428-07. No abstract available.

13.

Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages.

Helmers AJ, Gowda DC, Kain KC, Liles WC.

Am J Trop Med Hyg. 2009 Oct;81(4):631-7. doi: 10.4269/ajtmh.2009.09-0204.

14.

Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ.

Mol Cancer Ther. 2009 Jul;8(7):1799-807. doi: 10.1158/1535-7163.MCT-09-0055.

15.

Neuregulin-1 attenuates mortality associated with experimental cerebral malaria.

Solomon W, Wilson NO, Anderson L, Pitts S, Patrickson J, Liu M, Ford BD, Stiles JK.

J Neuroinflammation. 2014 Jan 17;11:9. doi: 10.1186/1742-2094-11-9.

16.

Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.

Mwangi VI, Mumo RM, Kiboi DM, Omar SA, Ng'ang'a ZW, Ozwara HS.

J Infect Dev Ctries. 2016 Jun 30;10(6):635-42. doi: 10.3855/jidc.7556.

17.

Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies.

Penna-Coutinho J, Cortopassi WA, Oliveira AA, França TC, Krettli AU.

PLoS One. 2011;6(7):e21237. doi: 10.1371/journal.pone.0021237.

18.
19.

Statins alone are ineffective in cerebral malaria but potentiate artesunate.

Bienvenu AL, Picot S.

Antimicrob Agents Chemother. 2008 Nov;52(11):4203-4. doi: 10.1128/AAC.00513-08. No abstract available.

20.

Schistosoma co-infection protects against brain pathology but does not prevent severe disease and death in a murine model of cerebral malaria.

Bucher K, Dietz K, Lackner P, Pasche B, Fendel R, Mordmüller B, Ben-Smith A, Hoffmann WH.

Int J Parasitol. 2011 Jan;41(1):21-31. doi: 10.1016/j.ijpara.2010.06.008.

PMID:
20708623

Supplemental Content

Support Center